An observational study in Pulmonary Disease, Chronic Obstructive, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2014-09-04.
Sponsored by Boehringer Ingelheim · Observational
The aim of this post-marketing surveillance is to obtain further information about the tolerability of Berodual® metered-dose inhaler in the treatment of chronic obstructive respiratory tract disease under conditions of daily practice
4,131 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 697 are open to participants now.
This study's enrollment of 3,488 is above the median of 180 across 1,066 observational studies indexed under Pulmonary Disease, Chronic Obstructive.
Browse Pulmonary Disease, Chronic Obstructive studies →Boehringer Ingelheim is the lead sponsor of 2,245 studies on the registry; 58 are open to participants now.
Of its 162 completed or terminated interventional studies of FDA-regulated products, 116 (72%) have results posted.
Counted across the registry records on this site, refreshed daily.
general practitioners, pneumologists and internists
Exclusion Criteria:
Drug: Berodual®
Overall severity of the clinical picture rated on a 4-point scale
Time frame: after 3 and 6 weeks
Changes in dyspnea and/or asthma attacks rated on a 4-point scale
Time frame: after 3 and 6 weeks
Number of dyspnea episodes rated on a 4-point scale
Time frame: after 3 and 6 weeks
Number of awakenings due to night-time dyspnea rated on a 4-point scale
Time frame: after 3 and 6 weeks
Assessment of morning coughing with expectoration on a 4-point scale
Time frame: after 3 and 6 weeks
Assessment of tolerability on a 4-point scale
Time frame: after 3 and 6 weeks
Number of patients with adverse drug reactions
Time frame: up to 6 weeks
Changes in pathological auscultation findings rated on a 3-point scale
Time frame: after 3 and 6 weeks
Changes in concomitant medication
Time frame: up to 6 weeks
Assessment of efficacy on a 4-point scale
Time frame: after 3 and 6 weeks
No study locations are listed for this record.
This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive→
Boehringer Ingelheim